Valentin Feichtenschlager, MD

Title(s)Postdoctoral Scholar, Dermatology
SchoolSchool of Medicine
Address2340 Sutter Street, #N461
San Francisco CA 94115
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Res Sq. 2023 Dec 01. Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. PMID: 38077055; PMCID: PMC10705697.
      View in: PubMed   Mentions:
    2. Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment. Oncotarget. 2023 05 26; 14:543-560. Feichtenschlager V, Zheng YJ, Ho W, Chen L, Callanan C, Chen C, Lee A, Ortiz J, Rappersberger K, Ortiz-Urda S. PMID: 37235843; PMCID: PMC10219656.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    3. 672 Targeting lncRNAs AC and BX reveals their critical role in melanoma and allows to identify novel phosphor-catalytic vulnerabilities. Journal of Investigative Dermatology. 2020 Jul 1; 140(7):s91. Feichtenschlager FV, Emily EC, Vujic VM, Vujic VI, Chen CC, Lee LA, Ortiz-Urda OS. .
      View in: Publisher Site   Mentions:
    4. Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010. Wien Med Wochenschr. 2019 Oct; 169(13-14):323-330. Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C. PMID: 30649651.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. 185 The antisense lncRNA transcript RP11-7O11.3: Shedding light upon a novel and crucial player in NRAS mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31. Chen CL, Feichtenschlager FV, Vujic VM, Lee LA, Kao KH, Zheng ZJ, Ortiz OS. .
      View in: Publisher Site   Mentions:
    6. 184 Discovering the hidden elements of cancer: Targeting the lncrna ac004540.4 reveals its critical role in nras mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31. Feichtenschlager FV, Chen CL, Vujic VM, Lee LA, Kao KH, Zheng ZJ, Ortiz OS. .
      View in: Publisher Site   Mentions:
    7. 497 Eleven years of melanoma patient management – observations and trends from a single-center study in Austria. Journal of Investigative Dermatology. 2016 Sep 1; 136(9):s245. Posch PC, Feichtenschlager FV, Weihsengruber WF, Rappersberger RK. .
      View in: Publisher Site   Mentions:
    8. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15; 5(17):7936-44. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. PMID: 25277205; PMCID: PMC4202171.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    9. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18; 110(6):1427-32. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. PMID: 24518593; PMCID: PMC3960625.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    10. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. PMID: 23431193; PMCID: PMC3593920.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansAnimalsCells
    Valentin's Networks
    Concepts (44)
    Derived automatically from this person's publications.
    Co-Authors (7)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department